Close Menu

NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed an expansion of its partnership with Maastricht University to develop genetic and epigenetic cancer diagnostics.

Under the terms of the multiyear deal, MDxHealth will collaborate with Maastricht's Faculty of Health, Medicine, and Life Sciences institute and its School for Oncology and Developmental Biology to develop genetic and epigenetic assays for diagnosing, staging, and treating cancer patients.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.